PROK2/PROKR2 signaling and Kallmann syndrome

Catherine Dodé1,* and Philippe Rondard2

1 INSERM U1016, Institut Cochin, Université Paris-Descartes, Paris, France
2 CNRS UMR9203, INSERM U681, Institut de Génomique Fonctionnelle, Université Montpellier 1, 2, Montpellier, France

*Correspondence: Catherine Dodé, INSERM U1016, Institut Cochin, Département de génétique et développement, 24 rue du Faubourg Saint-Jacques, 75014 Paris, France. e-mail: catherine.dode@inserm.fr

INTRODUCTION

Kallmann syndrome (KS) is a developmental disease that associates hypogonadotropic hypogonadism, and anosmia, related to the absence or hypoplasia of the olfactory bulbs (Kallmann, 1944; deMorsier, 1954; Naftolin et al., 1971). The degree of the hypogonadism and that of the smell deficiency can vary significantly, not only between unrelated KS patients, but also between patients from the same family. The prevalence of KS has been estimated at one out of 8000 in boys. In girls, the prevalence is thought to be five times lower, but it is probably underestimated because some affected females only have mild hypogonadism, and also because primary amenorrhea in females often remains unexplored (Jones and Kemmann, 1976).

Pathohistological studies of fetuses with olfactory bulb agenesis have shown that the reproductive phenotype of KS results from a pathological sequence in embryonic life, whereby premature interruption of the olfactory, vomeronasal, and terminal nerve fibers in the frontonasal region disrupts the migration of neuroendocrine GnRH cells, which normally migrate from the nose to the brain along these nerve fibers (Schwanzel-Fukuda and Pfaff, 1989; Teixeira et al., 2010). What causes the primary failure of these fibers to establish proper contact with the forebrain is, however, still unknown.

Kallmann syndrome (KS) is a developmental disease that associates hypogonadism and a deficiency of the sense of smell. The reproductive phenotype of KS results from the primary interruption of the olfactory, vomeronasal, and terminal nerve fibers in the frontonasal region, which in turn disrupts the embryonic migration of neuroendocrine gonadotropin-releasing hormone (GnRH) synthesizing cells from the nose to the brain. This is a highly heterogeneous genetic disease, and mutations in any of the nine genes identified so far have been found in approximately 30% of the KS patients. PROKR2 and PROK2, which encode the G protein-coupled prokineticin receptor-2 and its ligand prokineticin-2, respectively, are two of these genes. Homozygous knockout mice for the orthologous genes exhibit a phenotype reminiscent of the KS features, but biallelic mutations in PROKR2 or PROK2 (autosomal recessive mode of disease transmission) have been found only in a minority of the patients, whereas most patients carrying mutations in these genes are heterozygotes. The mutations, mainly missense mutations, have deleterious effects on PROKR2 signaling in transfected cells, ranging from defective cell surface-targeting of the receptor to defective coupling to G proteins or impaired receptor-ligand interaction, but the same mutations have also been found in apparently unaffected individuals, which suggests a digenic/oligogenic mode of inheritance of the disease in heterozygous patients. This non-Mendelian mode of inheritance has so far been confirmed only in a few patients. However, it may account for the unusually high proportion of KS sporadic cases compared to familial cases.

Keywords: PROK2, PROKR2, Kallmann syndrome, hypogonadotropic hypogonadism, anosmia, digenic/oligogenic mode of inheritance
Table 1 | KS genes

| Genes     | KAL1 | FGFR1 and FGFR8 | PROKR2 and PROKR2 | CHD7 | WDR11 | HS6ST1 | SEMA3A |
|-----------|------|-----------------|-------------------|------|-------|--------|--------|
| Mode(s) of transmission | X-linked recessive | Autosomal dominant (incomplete penetrance) or digenic/oligogenic | Autosomal recessive or digenic/oligogenic | ?   | ?    | digenic/oligogenic? | digenic/oligogenic? |
| Strategy for gene identification | Cytogenetics | Cytogenetics and mouse model | Mouse models | Candidate gene | C. elegans model | Mouse model |
| Prevalence of mutations in KS patients | 8% of male patients | 10 and <1% | 7 and 3% | 1–5% | <1% | <1% | 6% |
| Reference | Legouis et al. (1991), Franco et al. (1991), Hardelin et al. (1992) | Dodé et al. (2003), Falardeau et al. (2008) | Dodé et al. (2006) | Kim et al. (2008), Jongmans et al. (2009) | Kim et al. (2010) | Tornberg et al. (2011) | Hanchate et al. (2012), Young et al. (2012) |

7, not known.

all KS cases, respectively. The KAL1 gene product, anosmin-1, binds to heparan-sulfate glycosaminoglycans, and may act as a coreceptor for FGF signaling through FGFR1, which also requires interaction with heparan-sulfate glycosaminoglycans for receptor activation. Mutations in the genes encoding heparan-sulfate 6-O-sulfotransferase 1, an enzyme involved in glycosaminoglycan modifications, WDR11, an intracellular protein that interacts with the transcription factor EMX1, and semaphorin 3A, a secreted protein involved in axonal pathfinding, have also been found in some KS patients. Mutations in the chromodomain helicase DNA-binding protein 7 gene (CHD7) are present in approximately 70% of the patients affected by the CHARGE syndrome, which in most patients includes KS (Pinto et al., 2005), and mutations in this gene have been found in some patients who initially presented with KS. Finally, mutations in PROKR2 and PROKR2, encoding prokineticin receptor-2 and prokineticin-2, respectively, have been identified in approximately 9% of the KS patients, both in heterozygous and in homozygous or compound heterozygous states.

PROKINETICINS AND THEIR RECEPTORS

Prokineticins are secreted cysteine-rich proteins that possess diverse biological activities. The first identified member of this family was isolated from the venom of the black mamba snake (Joubert and Strydom, 1980), and was named mamba intestinal toxin 1 (MIT1) owing to its ability to induce intestinal contraction (Schweitz et al., 1999). Then, a small protein of similar size (77 amino acid residues, 8 kDa), with 58% sequence identity with MIT1, was isolated from skin secretions in the amphibian Bombina variegata, and called Bv8 (Mollay et al., 1999). Soon after, two mammalian proteins of this family were identified and named prokineticin-1 and -2 (PROK1 and PROK2) (Li et al., 2001; Kaser et al., 2003). PROK1 has 80% sequence identity with MIT1 and 58% identity with PROK2 (Li et al., 2001). The amino-terminal domain of prokineticins contains a sequence of six amino acid residues (AVITGA), which is conserved in all mammalian and non-mammalian orthologs. Substitutions, deletions, or insertions to this hexapeptide result in the loss of agonist activity on prokineticin receptors (Kaser et al., 2003; Bullock et al., 2004). The carboxy-terminal region of prokineticins contains 10 cysteine residues forming five disulfide bonds. Apart from its potent effect on gastrointestinal smooth muscle contraction, PROK1 was also characterized as an angiogenic factor with specific effects on steroidogenic glands, thus earning its initial name EG-VEGF (endocrine gland vascular endothelial growth factor) (LeCouter et al., 2003). Mouse and human orthologs of Bv8, also known as PROK2, have been involved in a variety of biological activities, including effects on neuronal survival, gastrointestinal smooth muscle contraction (Li et al., 2001), circadian locomotor rhythm (Cheng et al., 2002), survival and migration of adrenal cortical capillary endothelial cells (LeCouter et al., 2003). PROK2 also has a role in appetite regulation and its anorectic effect is mediated partly by the melanocortin system (Gardiner et al., 2006).

Prokineticins can bind to two different G protein-coupled receptors, prokineticin receptor-1 and -2 (PROKR1 and PROKR2), which have about 85% sequence identity. These receptors were characterized simultaneously by three different groups (Lin et al., 2002; Masuda et al., 2002; Soga et al., 2002). Both are able to bind to PROK1 and PROK2 with similar nanomolar range affinities. They have a central core formed by seven transmembrane α-helical segments (TM1–TM7) connected by intracellular (i1–i3) and extracellular (e1–e3) loops, an extracellular aminoterminal end, and an intracellular carboxy-terminal end. These plasma membrane receptors operate as molecular switches to relay extracellular ligand-activation to intracellular heterotrimeric G proteins. PROKR1 is mainly expressed in peripheral tissues, including endocrine glands and organs of the reproductive system, the gastrointestinal tract, lungs, and the circulatory system (Soga et al., 2002; Battersby et al., 2004), whereas PROKR2 shows relatively localized distribution in the central nervous system (Cheng et al., 2002; Lin et al., 2002).
The olfactory bulb is one of the few areas in the mammalian brain that produce neurons throughout life. New interneurons originating from progenitors in the subventricular zone (SVZ) are continually added to the olfactory bulbs. The mRNAs of both receptors (PROKR1 and PROKR2) are expressed in the SVZ and the olfactory bulbs. The expression of PROKR1 has been detected in these areas although less abundantly than PROKR2. Whereas PROK1 mRNAs were not detected in any of these brain region (Ng et al., 2005). It was first shown that PROK2 functions as a chemoattractant for these neuronal progenitors, which follow a rostral migratory stream. Accordingly, PROK2 deficiency in mice leads to a loss of normal olfactory bulb architecture, and accumulation of neuronal progenitors in the rostral migratory stream (Ng et al., 2005). Soon after, it was found that Prokr2<sup>-/-</sup> knockout mice exhibit early hypoplasia of the olfactory bulbs and severe atrophy of the reproductive organs in both sexes, a phenotype reminiscent of the KS features. In addition, immunohistochemical analysis of these mice revealed that the neuroendocrine GnRH cells were absent from the hypothalamus (Matsumoto et al., 2006).

PROK2 is a clock-controlled gene: the level of its messenger RNA shows a circadian oscillation profile in the suprachiasmatic nuclei (Cheng et al., 2002; Li et al., 2006). It has been postulated that PROK2 signaling through PROKR2 is a suprachiasmatic nuclei clock output signal that regulates circadian rhythms (Prosser et al., 2007; Li et al., 2012). PROK2-null mice show accelerated acquisition of food anticipatory activity during a daytime food restriction (Li et al., 2006), exhibit reduced total sleep time predominantly during the light period, and also have an impaired response to sleep disturbance (Hu et al., 2007).

PROK2 is a functional target gene of proneural basic helix-loop-helix (bHLH) factors. Neurogenin-1 (NGN1) and MASH1 activate PROK2 transcription by binding to E-box motifs on the PROK2 promoter with the same set of E-boxes critical for another pair of bHLH factors, CLOCK and BMAL1, in the regulation of circadian clock (Cheng et al., 2002; Zhang et al., 2007).

**COMPLEX GENETICS OF KALLMANN SYNDROME CAUSED BY MUTATIONS IN PROKR2 OR PROK2**

We first considered that PROK2 was a relevant KS candidate because of the KS-like phenotype of PROK2-null mice (see above). We thus sequenced the two coding exons of PROK2 in a cohort of patients affected by KS, and identified 10 different mutations (one frame-shifting and nine missense mutations) in 14 patients, either in heterozygous state (10 cases) or in homozygous or compound heterozygous state (4 cases) (Dodé et al., 2006) (Table 2). Notably, most of these mutations were missense mutations, and many were also found in apparently unaffected individuals, thus initially raising some questions regarding their pathogenic role. A deleterious effect on the signaling activity of PROK2 was, however, confirmed in transfected HEK-293 cells for most of the mutations (Cole et al., 2008; Monnier et al., 2009).

Then, we considered the possibility that mutations in PROK2 also account for some KS cases, especially since mutant mice defective in PROK2 showed a marked reduction in the size of their olfactory bulbs. PROK2 contains four coding exons (Bullock et al., 2004), of which exon 3, encoding an arginine- and lysine-rich peptide of 21 amino acid residues, may or may not be included in the mature transcript due to alternative splicing (Wechselberger et al., 2009) (Figure 1). We sequenced the entire coding sequence of PROK2 in the patients, and identified four different point mutations (two missense mutations, one frame-shifting mutation, and one single nucleotide substitution in the translation initiation sequence), all in the heterozygous state (Dodé et al., 2006). PROK2 mutations in homozygous state were subsequently found in a few patients, and a KS-like phenotype was concomitantly reported in PROK2-null mutant mice (Pitteloud et al., 2007; Leroy et al., 2008). Since then, additional mutations in PROKR2 and PROK2 have been reported in KS patients. A list of the mutations, together with the corresponding references, is provided in Table 2.

The finding, for given PROKR2 and PROK2 mutations, of both heterozygous and homozygous (or compound heterozygous) unrelated patients is quite remarkable, and argues in favor of a digenic or oligogenic mode of inheritance in heterozygous patients. To date, digenic inheritance of KS has been shown in few patients who had monoallelic missense mutations both in PROKR2 or PROK2, and in other KS genes (KAL1, FGFR1) or genes underlying normosmic congenital hypogonadotrophic hypogonadism (GNRHR, KISS1R) (Dodé et al., 2006; Cole et al., 2008; Raivo et al., 2009; Martin et al., 2010; Sarfati et al., 2010). The other patients harboring monoallelic mutations in PROKR2 or PROK2 are expected to carry at least one additional pathogenic mutation in as yet uncharacterized genes. Indeed, mutations in any of the currently known KS genes have been identified in only 30% of all KS patients, thus indicating that other disease genes remain to be discovered. Notably, it has been found that patients carrying biallelic mutations in PROKR2 or PROK2 consistently have a severe, complete KS phenotype, whereas the phenotype of patients carrying monoallelic mutations in these genes is more variable, and likely depends on the additional genetic hits in these patients (Martin et al., 2010; Sarfati et al., 2010).

Kallmann syndrome patients who carry biallelic mutations in PROKR2 or PROK2 do not seem to have any of the non-olfactory, non-reproductive occasional anomalies that have been reported in the previously characterized genetic forms of the disease (i.e., X-linked KAL1 form and autosomal dominant KAL2 form), specifically, bimanual synkinesis, renal agenesis, dental age-nis, and cleft lip or palate, and even though sleep disorders or increased body mass index have been reported in some of these patients, there is so far no evidence that these clinical features can be ascribed to the PROKR2 and PROK2 mutations, despite potential roles of these genes in sleep-wake regulation and ingestive behavior (see above). In addition, plasma cortisol levels were measured during 24 h in five patients mutated in PROK2 or PROKR2, including one patient with biallelic PROK2 mutations, and normal circadian variation was observed in all cases (Sarfati et al., 2010), which argues against a major contribution of PROK2/PROKR2 signaling to physiological circadian variation of plasma cortisol levels in humans. Of course, this result does not exclude the presence of more subtle defects in the patients.

**CONSEQUENCES OF THE PROKR2 AND PROK2 MISSENSE MUTATIONS ON RECEPTOR SIGNALING ACTIVITY**

A total of 24 PROKR2 missense mutations have been identified (Dodé et al., 2006; Cole et al., 2008; Sinisi et al., 2008; Chan et al., 2009; Abreu et al., 2010; Sarfati et al., 2010) in KS patients (Table 2;
Table 2 | PROKR2 and PROK2 mutations in Kallmann syndrome.

| Exon | Nucleotide change | Amino acid change | Localization (domain) | Functional consequence | Reference |
|------|-------------------|------------------|----------------------|------------------------|-----------|
| PROKR2 | 1  | 58del | Frameshift | N-terminal region | NMD or protein truncation | Dodé et al. (2006) |
| | | 151G > A | A51T | N-terminal region | None? | Reynaud et al. (2012), Sbai et al. (unpublished) |
| | | 238C > T | R80C | First intracellular loop | None? | Abreu et al. (2010), Sbai et al. (unpublished) |
| | | 253C > T | R85C | – | Mild G protein-coupling defect | Cole et al. (2008), Monnier et al. (2009), Sarfati et al. (2010) |
| | | 253G > T | R85G | – | Strong G protein-coupling defect | Sarfati et al. (2010), Raivio et al. (2012) |
| | | 254G > T | R85L | – | Mild protein-coupling defect | Sarfati et al. (2010), Sbai et al. (unpublished) |
| | | 254G > A | R85H | – | Mild G protein-coupling defect | Dodé et al. (2006), Monnier et al. (2009) |
| | | 337T > C | Y113H | First extracellular loop | Strong G protein-coupling defect | Cole et al. (2008), Sbai et al. (unpublished) |
| | | 343G > A | V115M | – | Strong G protein-coupling defect | Cole et al. (2008), Sbai et al. (unpublished) |
| | | 349C > T | R117W | – | Strong G protein-coupling defect | Sbai et al. (unpublished) |
| | | 420C > G | Y140X | Third transmembrane domain | NMD or protein truncation | Abreu et al. (2010) |
| | 2 | 491G > A | R164Q | Second intracellular loop | Mild G protein-coupling defect | Dodé et al. (2006), Cole et al. (2008), Monnier et al. (2009) |
| | | 518T > G | L173R | Fourth transmembrane domain | Cell surface-targeting defect | Dodé et al. (2006), Abreu et al. (2010), Cole et al. (2008), Monnier et al. (2009) |
| | | 533G > C | W178S | – | Cell surface-targeting defect | Dodé et al. (2006), Cole et al. (2008), Monnier et al. (2009) |
| | | 563C > T | S188L | – | Strong G protein-coupling defect | Cole et al. (2008), Sbai et al. (unpublished) |
| | | 604A > G | S202G | Second extracellular loop | ? | Chan et al. (2009) |
| | | 629A > G | Q210R | – | Ligand-binding defect | Dodé et al. (2006), Monnier et al. (2009) |
| | | 701G > A | G234D | Fifth transmembrane domain | Cell surface-targeting defect | Sbai et al. (unpublished) |
| | | 743G > A | R248Q | Third intracellular loop | None? | Cole et al. (2008) |
| | | 752G > T | W251L | – | Strong G protein-coupling defect? | Sarfati et al. (2010), Sbai et al. (unpublished) |
| | | 802C > T | R268C | – | G protein-coupling defect? | Dodé et al. (2006), Abreu et al. (2010), Monnier et al. (2009), Sarfati et al. (2010) |
| | | 868C > T | P290S | – | Cell surface-targeting defect | Dodé et al. (2006), Monnier et al. (2009) |
| | | 969G > A | M323I | Seventh transmembrane domain | None? | Dodé et al. (2006), Monnier et al. (2009) |
| | | 999del | Frameshift | – | NMD or protein truncation | Sarfati et al. (2010) |
| | | 991G > A | V331M | – | Mild G protein-coupling defect | Dodé et al. (2006), Cole et al. (2008), Monnier et al. (2009), Sarfati et al. (2010) |
| | | 1069C > T | R357W | C-terminal region | None? | Cole et al. (2008), Sbai et al. (unpublished) |

(Continued)
Table 2 | Continued

| Exon | Nucleotide change | Amino acid change | Localization (domain) | Functional consequence | Reference |
|------|------------------|------------------|-----------------------|-----------------------|-----------|
| 1    | −4C > A          |                  | Translation initiation site | Reduced protein synthesis? | Dodé et al. (2006) |
| −    | 70G > C          | A24P             | Signal peptide         | ?                     | Cole et al. (2008) |
| −    | 94G > C          | G32R             | AVITGA motif           | Strongly impaired activity? | Dodé et al. (2006) |
| 2    | 101 G > A        | C34Y             | Cysteine-rich region   | Strongly impaired activity | Cole et al. (2008) |
| −    | 137G > A         | C48Y             | Cysteine-rich region   | ?                     | Dodé et al. (unpublished) |
| −    | 150C > G         | I50M             | –                     | None?                 | Cole et al. (2008) |
| −    | 161G > A         | S64N             | –                     | ?                     | Sarfati et al. (2010) |
| −    | 163del           | Frameshift       | –                     | NMD or protein truncation | Pitteloud et al. (2007), Leroy et al. (2008) |
| −    | 217C > T         | R73C             | –                     | Strongly impaired activity | Dodé et al. (2006), Leroy et al. (2008), Cole et al. (2008) |
| 4    | 297_298insT      | Frameshift       | –                     | NMD or protein truncation | Dodé et al. (2006), Abreu et al. (2010) |
| −    | 301C > T         | R101W            | –                     | ?                     | Dodé et al. (unpublished) |
| −    | 302G > A         | R101Q            | –                     | ?                     | Dodé et al. (unpublished) |
| −    | 310C > T         | H104Y            | –                     | ?                     | Sarfati et al. (2010) |

Mutations reported in PROKR2 and PROK2 are mainly missense mutations. In most patients, the mutations have been found in heterozygous state. The R85C, R85H, R164Q, L173R, and P290S PROKR2 mutations, as well as R73C, c.163del, and c.297_298insT PROK2 mutations have, however, been found both in heterozygous and homozygous (or compound heterozygous) states, which suggests that patients heterozygous for PROKR2 or PROK2 mutations carry additional mutations, presumably in other, as yet unidentified Kallmann syndrome genes in most cases. Notably, two such patients have the L173R mutation in PROKR2 together with S396L or R423X mutations in KAL1 (Dodé et al., 2006; Sarfati et al., 2010), another patient has the V115M mutation in PROKR2 together with the A24P mutation in PROK2 (Cole et al., 2008), and still another patient has the R85L mutation in PROKR2 together with a A604T mutation in FGFR1 (Sarfati et al., 2010). In addition, the patient who has the S202G mutation in PROKR2 also has I239T and R31C monoallelic mutations in FGFR1 and GNRH1, respectively (Chan et al., 2009). Finally, two patients who carry R268C and V331M mutations in PROKR2 also carry A189T and R240Q monoallelic mutations in KISS1R and GNRHR, respectively (Sarfati et al., 2010). Abbreviation: NMD, nonsense-mediated mRNA decay.

Figure 2). Most of the mutant receptors have been characterized regarding their ability to induce intracellular release of calcium upon PROK2-stimulation, their cell surface expression, and their PROK2-binding, in mammalian cell lines (Cole et al., 2008; Monnier et al., 2009; Abreu et al., 2012; Raivio et al., 2012; Sbai et al., in preparation). Although PROKR2 can activate different
G protein pathways (Lin et al., 2002; Soga et al., 2002; Chen et al., 2005), its coupling to Gq, leading to intracellular release of calcium, represents the best characterized transduction mechanism. Only five mutants (A51T, R80C, R248Q, M321I, R357W) have properties similar to the wild-type PROKR2, thus calling into question the pathogenic effect of these missense variants. Notably, the R268C mutation has also been found in heterozygous state in a relatively large proportion (174 out of 2203, i.e., 7.9%) of individuals from the African American general population, and in homozygous state in six individuals from the same population (0.3%; see Exome Variant Server website URL: http://evs.gs.washington.edu/EVS/). Moreover, a clear deleterious effect of the R268C mutation has also been found in transfected HEK-293 cells, none of the mutant receptors that were retained within the cells did affect cell surface-targeting of the wild-type receptor, and none of the mutant receptors properly addressed at the plasma membrane did affect wild-type receptor signaling activity. This argues against a dominant negative effect of the mutations in vivo.

A total of 10 missense mutations have been identified in PROK2 (Table 2, Figure 2) (Dodé et al., 2006; Cole et al., 2008; Leroy et al., 2008; Sarfati et al., 2010). A mutation located at the translation initiation site (−4C→A) likely reduced the protein synthesis. Mutations of conserved residues in prokineticins are expected to strongly impair PROK2 activity such as those in the N-terminal conserved region AVITGA important for prokineticin activity (G32R), and those of the conserved cysteines (C34Y and C46Y). In addition, mutations that introduce an additional cysteine (R73C) in the cysteine-rich region of PROK2 may affect folding of the hormone then leading to a loss-of-function. This is consistent with the functional analysis of Cole et al. (2008) who have examined the signaling properties of three PROK2 mutants: the C34Y and R73C mutations totally abolished and strongly impaired the intracellular calcium release activity of PROKR2, respectively, whereas the I50M mutation had an activity similar to that of the wild-type PROK2. The functional consequence of the other mutations (A24P, S54N, R101Q, R101W, and H104Y) are more difficult to predict in the absence of model of the complex between PROK2 and PROKR2. Further studies will be necessary to better analyze whether the mutations in PROK2 affect the process of binding and/or activation of PROKR2 by the hormone.

CONCLUSION

The characterization of new genes involved in KS is a difficult goal. Because of the hypogonadotropic hypogonadism, sizes of the KS families are small and the mode of inheritance is very often difficult to establish. Animal models in which a gene has been inactivated and involving a KS phenotype are an alternative approach for the identification of new KS genes. The inactivation of PROK2 or PROKR2 lead to defective olfactory morphogenesis and hypogonadism in mice and humans. Curiously, PROK2 and PROKR2 mutations in homozygous state were found in a few patients and the main part of the KS patients carried only heterozygous mutations. In all of the functional studies done so far, only Gq signaling pathways have been investigated to characterize the PROK2 and PROKR2 mutants and further studies will be necessary to analyze other signaling pathways. Interestingly, few patients who had monoallelic

FIGURE 2 | Positions of missense mutations in PROK2 and PROKR2 in the structural models of the ligand and the receptor. The mutations are classified in different categories according to their effects on PROK2 signaling activity: similar to wild-type (green), absence of the receptor at the cell surface (brown), absence of ligand-binding (blue), and strong or mild effect on signaling (red and orange, respectively). The mutations for which functional data are not available are denoted in black. The colored balls indicate the atom of alpha carbon of the polypeptidic chain of the mutated residue. Note that residue R357 is located in the proximal part of the C-terminal region of the receptor.

TABLE 1 | Missense mutations in the PROK2 and PROKR2 genes.

| Mutation | Cell surface expression | Ligand-binding | G protein-binding | Pathogenic effect |
|----------|-------------------------|----------------|-------------------|------------------|
| A51T     | No cell surface expression | No binding | No signal of G protein | Likely reduced protein synthesis |
| R80C     | No cell surface expression | No binding | No signal of G protein | Likely reduced protein synthesis |
| R248Q    | No cell surface expression | No binding | No signal of G protein | Likely reduced protein synthesis |
| M321I    | No cell surface expression | No binding | No signal of G protein | Likely reduced protein synthesis |
| R357W    | No cell surface expression | No binding | No signal of G protein | Likely reduced protein synthesis |
| C32G     | Present at the cell surface | Presence of ligand | Presence of signal of G protein | Similar to wild-type |
| A51T     | Present at the cell surface | Presence of ligand | Presence of signal of G protein | Similar to wild-type |
| R80C     | Present at the cell surface | Presence of ligand | Presence of signal of G protein | Similar to wild-type |
| R248Q    | Present at the cell surface | Presence of ligand | Presence of signal of G protein | Similar to wild-type |
| M321I    | Present at the cell surface | Presence of ligand | Presence of signal of G protein | Similar to wild-type |
| R357W    | Present at the cell surface | Presence of ligand | Presence of signal of G protein | Similar to wild-type |

Frontiers in Endocrinology | Neuroendocrine Science

April 2013 | Volume 4 | Article 19 | 6
missense mutations both in PROK2 or PROKR2, and in other KS or normosmic congenital hypogonadotropic hypogonadism genes, raising the idea of oligogenism. So far, this hypothesis has been validated only in a few patients suggesting that the second mutation in the other heterozygous patients resides in unexplored regions of the genes or as yet undiscovered KS genes.

ACKNOWLEDGMENTS

We thank Jean-Pierre Hardelin for critical reading of the manuscript, Ouaidil Sbai and Carine Monnier for sharing unpublished data, and Guillaume Lebon for his help in preparing the 3D models of PROK2 and PROKR2. This work was supported by ANR-09-GENO-017-01 and GIS maladies rares (Project A09051KS).

REFERENCES

Abreu, A. P., Kaiser, U. B., and Latronico, A. C. (2010). The role of prokineticins in the pathogenesis of hypogonadotropic hypogonadism. Neuroendocrinology 91, 283–290.

Abreu, A. P., Noel, S. D., Xu, S., Carroll, B. S., Latronico, A. C., and Kaiser, U. B. (2012). Evidence of the importance of the first intracellular loop of prokineticin receptor 2 in receptor function. Mol. Endocrinol. 26, 1417–1427.

Battersby, S., Critchley, H. O., Morgan, K., Millar, R. P., and Ibbotson, H. N. (2004). Expression and regulation of the prokineticins (endocrine gland-derivered vascular endothelial growth factor and Bv8) and their receptors in the human endometrium across the menstrual cycle. J. Clin. Endocrinol. Metab. 89, 2463–2469.

Bullock, C. M., Li, L.-D., and Zhou, Q.-Y. (2004). Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists. Mol. Pharmacol. 65, 582–588.

Chan, Y. M., de Guillebon, A., Lang-Muritano, M., Plummer, L., Cerrato, E., Tiara, S., et al. (2009). GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc. Natl. Acad. Sci. U.S.A. 106, 11703–11708.

Chen, J., Kuei, C., Sutton, S., Wilson, S., Yu, J., Kammé, F., et al. (2005). Identification and pharmacological characterization of prokinetin 2 β as a selective ligand for prokinetin receptor 1. Mol. Pharmacol. 67, 2070–2076.

Cheng, M., Bullock, C. M., Li, C., Lee, A. G., Bermak, J. C., Belluzzi, J., et al. (2002). Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 417, 405–410.

Cole, L. W., Sidis, Y., Zhang, C., Quinlan, R., Plummer, L., Pignatelli, D., et al. (2008). Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J. Clin. Endocrinol. Metab. 93, 3558–3559.

DeMorsier, G. (1954). Etudes sur les dysraphies crâneo-encephaliques. I. Agénésie des lobes olfactifs (te lancéphalochildis latéral) et des commissures calleuse et antérieure (te lancéphalochildis médian). La dysplasie olfacto-génitale. Schweiz. Arch. Neurol. Psychiatr. 74, 309–361.

Dodé, C., and Hardelin, J.-P. (2009). Kallmann syndrome. Eur. J. Hum. Genet. 17, 139–146.

Dodé, C., Lefèvres, J., Dupont, J.-M., De Paepe, A., De Dô, N., Souassi-Yanicostas, N., et al. (2003). Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat. Genet. 33, 463–465.

Dore, C., Teixeira, L., Lefervier, J., Fouveaut, C., Bouchard, P., Kottler, M.-L., et al. (2006). Kallmann syndrome: mutations in genes encoding prokinetin-2 and prokineticin receptor-2. PLoS Genet. 2:e175. doi:10.1371/journal.pgen.0020175.

Falardeau, I., Cheng, W. C., Beenken, A., Ravio, T., Plummer, L., Sidis, Y., et al. (2008). Decreased FGFR8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J. Clin. Invest. 118, 2822–2831.

Franco, B., Giuoli, S., Pragialis, A., Incerti, B., Bardoni, B., Tonlorenzi, R., et al. (1991). A gene deleted in Kallman’s syndrome shares homology with nuclear cell adhesion and axonal path-finding molecules. Nature 353, 529–536.

Gardiner, J. V., Bataveljic, A., Patel, N. S., Zang, X., Kurth, I., and Lan, F. (2006). Prokineticin-2 is a hypothalamic neuropeptide that potently inhibits food intake. Diabetes 56, 397–406.

Hanchate, N. K., Giacobini, P., Lhuillier, P., Parkash, I., Espy, C., Fouveaut, C., et al. (2012). SEMA3A, a gene involved in axonal pathfinding, is mutated in some patients with Kallmann syndrome. PLoS Genet. 8:e1002896. doi:10.1371/journal.pgen.1002896.

Hardelin, J.-P., Lefèvres, J., de Castelo, I., Cohen-Salmon, M., Legouis, R., Martin, C., Balasubramanian, R., et al. (2010). WDR11, a WD protein that interacts with transcription factor ESM1, is mutated in idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am. J. Hum. Genet. 87, 465–479.

Hardelin, J.-P., Lefèvres, J., Chen, Y., Valleron, A.-J., Legouis, R., and Strydom, D. J. (1980). Expression and regulation of the prokineticins (endocrine gland-derivered vascular endothelial growth factor and Bv8) and their receptors to endothelial cells. J. Clin. Endocrinol. Metab. 65, 582–588.
Mollay, C., Wechselberger, C., Mignogna, G., Negri, L., Melchiorri, P., Barra, D., et al. (1999). Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur. J. Pharmacol. 374, 189–196.

Momier, C., Dodé, C., Fabre, L., Teixeira, L., Labesse, G., Pin, J.-P., et al. (2009). PROKR2 missense mutations associated with Kallmann syndrome impair receptor signalling activity. Hum. Mol. Genet. 18, 75–81.

Nafiolin, F., Harris, G. W., and Bonthron, M. (1971). Effect of purified lutetising hormone releasing factor on normal and hypogonadotropic anosmic men. Nature 232, 496–497.

Ng, K. L., Li, J.-D., Cheng, M. Y., Leslie, F. M., Lee, A. G., and Zhou, Q.-Y. (2005). Dependence of olfactory bulb morphogenesis on prokineticin 2 signaling. Nature 308, 1923–1927.

Pinto, G., Abadie, V., Mesnage, R., Illustajt, J., Cabrol, S., et al. (2005). CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. J. Clin. Endocrinol. Metab. 90, 5621–5626.

Pitteloud, N., Zhang, C., Pignatelli, M., Monnier, C., Dodé, C., Fabre, L., Teixeira, L., Labesse, G., Pin, J.-P., et al. (2009). PROKR2 missense mutations associated with Kallmann syndrome impair receptor signalling activity. Hum. Mol. Genet. 18, 75–81.

Pinto, G., Abadie, V., Mesnage, R., Illustajt, J., Cabrol, S., et al. (2005). CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. J. Clin. Endocrinol. Metab. 90, 5621–5626.

Sinisi, A. A., Ascì, R., Bellastella, G., Maione, L., Esposito, D., Elefante, A., et al. (2008). Homozygous mutation in the prokineticin-receptor 2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: case report. Hum. Reprod. 23, 2380–2384.

Soga, T., Matsumoto, S., Oda, T., Saito, T., Hiyama, H., Takasaki, J., et al. (2002). Molecular cloning and characterization of prokineticin receptors. Biochim. Biophys. Acta 1579, 173–179.

Sykiotis, G. P., Plummer, L., Hughes, V. A., Au, M., Durrani, S., Nayak, Young, S., et al. (2010). Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc. Natl. Acad. Sci. U.S.A. 107, 15140–15144.

Teixeira, L., Guimiot, F., Dodé, C., Fallet-Bianco, C., Millar, R. P., Delezoide, A.-L., et al. (2010). Defective migration of neuroendocrine GnRH cells in human arhinencephalic conditions. J. Clin. Invest. 120, 3668–3672.

Tornberg, J., Sykiotis, G. P., Keefe, K., Plummer, L., Hoang, X., Hall, J. E., et al. (2011). Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotropic hypogonadism. Proc. Natl. Acad. Sci. U.S.A. 108, 11524–11529.

Wechselberger, C., Puglisi, R., Engel, E., Lepperding, G., Boitani, C., and Kreil, G. (1999). The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes. FEBS Lett. 462, 177–181.

Young, L., Metay, C., Bouligand, J., Tou, B., Franchou, B., Maione, L., et al. (2012). SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. Hum. Reprod. 27, 1460–1465.

Zhang, C., Ng, K. L., Li, J.-D., He, F., Anderson, D. J., Sun, Y. E., et al. (2007). Prokineticin 2 is a target gene of pronuclear basal helix loop-helix factors for olfactory bulb neurogenesis. J. Biol. Chem. 282, 6917–6921.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.